Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QUOTED. Aparna Higgins.

Executive Summary

A panel of experts discussed the fate of the Medicare Coverage for Innovative Technology (MCIT) rule during AdvaMed’s annual Medtech Conference. Aparna Higgins, a senior policy fellow at the Duke-Margolis Center for Health Policy, stressed that FDA and CMS criteria are not the same.

“The evidence standards that are used to satisfy FDA safety and effectiveness criteria are not the same that Medicare uses in terms of determining what is reasonable and necessary,” she said, “and there's also no way to ensure that there will be evidence upon approval that shows the benefits or risks for Medicare beneficiaries in clinical trials and there is no authority to limit or remove coverage.” – Aparna Higgins, senior policy fellow, Duke-Margolis Center for Health Policy

Click here for a free trial of Medtech Insight

Related Content

Topics

UsernamePublicRestriction

Register

MT144530

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel